Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 21, 2025
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registryMaria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, et al.
Melanoma Research|September 3, 2025
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 studyPablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, et al.
Nature Medicine|October 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trialGeorgina V Long, Charlie Garnett-Benson, Sonia Dolfi, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Nature Medicine|June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFRMiguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)Michael K Wong, Mohammed M Milhem, Joseph J Sacco, et al.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 20, 2025
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, Eva Muñoz-Couselo, et al.
Nature Genetics|February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 21, 2025
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registryMaria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, et al.
Melanoma Research|September 3, 2025
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 studyPablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, et al.
Nature Medicine|October 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trialGeorgina V Long, Charlie Garnett-Benson, Sonia Dolfi, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Nature Medicine|June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFRMiguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)Michael K Wong, Mohammed M Milhem, Joseph J Sacco, et al.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 20, 2025
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, Eva Muñoz-Couselo, et al.
Nature Genetics|February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesLuping Lin, Amit J Sabnis, Elton Chan, et al.
Pageof 8